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Abstract 
 
Objective: Migrants account for a significant number of people living with HIV in Europe, 
and it is important to fully consider this population in national estimates. Using a novel 
approach with the UK as an example, we present key public health measures of the HIV 
epidemic, taking into account both in-country infections and infections likely to have been 
acquired abroad. 
Design: Mathematical model calibrated to extensive data sources. 
Methods: An individual-based stochastic simulation model is used to calibrate to routinely 
collected surveillance data in the UK. Data on number of new HIV diagnoses, number of 
deaths, CD4 count at diagnosis, as well as time of arrival into the UK for migrants and the 
annual number of people receiving care were used.  
Results: An estimated 106,400 (90% plausibility range: 88,700-124,600) people were living 
with HIV in the UK in 2013. 23% of these people, 24,600 (15,000-36,200) were estimated to 
be undiagnosed; this number has remained stable over the last decade. An estimated 32% of 
the total undiagnosed population have CD4 count <350 cells/mm3 in 2013. 25% and 23% of 
black African male and female heterosexuals living with HIV were undiagnosed respectively.  
Conclusions: We have shown a working example to characterize the HIV population in a 
European context which incorporates migrants from countries with generalised epidemics. 
Despite all aspects of HIV care being free and widely available to anyone in need in the UK, 
there is still a substantial number of people who are not yet diagnosed and thus not in care.  
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Introduction 
It is imperative for countries to have a good understanding of the populations most at risk of 
and affected by HIV infection, so as to inform and evaluate the public health response to the 
epidemic, including the targeting of prevention efforts and to adequately fund treatment and 
health care services. Monitoring and surveillance is vital to achieve this, and in combination 
with modelling techniques, data generated can be used to estimate the size of the undiagnosed 
and diagnosed population as well as HIV incidence[1-5]. One major limitation of much 
modelling work however, has been assumption that HIV was acquired within the country. 
This is one of the reasons why estimates of undiagnosed infections and incidence have 
focused predominantly on men-who-have-sex-with-men (MSM)[6-8]. In the UK, where all 
HIV services are provided free at the point of need, much research estimating the extent to 
which HIV affects the population has also focussed predominantly on MSM[4, 5]. The 
number of new diagnoses in MSM continues to rise[6], and is believed to be a result of a rise 
in HIV incidence over time as well as improved testing[5, 6, 9]. In contrast, the number of 
diagnoses of HIV acquired through heterosexual contact has gradually declined, mainly due 
to fewer diagnoses among people born in countries with generalised HIV epidemics, 
specifically sub-Saharan Africa[10]. However, this group still constitutes the second largest 
proportion of people living with HIV (PLHIV) in the UK. Furthermore, there is some 
evidence that the proportion of migrants with HIV who have acquired HIV within the UK has 
increased[11-13].  
Most estimates of key measures to describe HIV-positive populations in the UK are derived 
using, but not limited to, case-based surveillance of new diagnoses, CD4 counts at time of 
diagnosis and the number of deaths in diagnosed people[1]. We have previously reported on a 
method of estimation, demonstrated using data on the HIV-positive MSM population in the 
UK[14]. Here, we build on this previous work and extend it to map out the national epidemic 
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whilst taking into account migration of people from sub-Saharan Africa, which is rarely 
considered explicitly in other back-calculation and modelling studies[6-8]. The main aim of 
this work is to demonstrate a novel approach using a mathematical model with the UK as an 
example, to present key public health outputs on the national level, including the size of the 
undiagnosed population and HIV incidence for PLHIV.  
 
Methods 
The model 
The HIV Synthesis progression model is an individual-based stochastic simulation model of 
HIV progression and the effect of antiretroviral therapy (ART). Model details are available 
elsewhere[15-17]. In brief, the model aims to simulate the course of HIV infection by 
following them over time in three monthly intervals. Model assumptions and variables are 
based on data from observational cohort studies and clinical trials. Variables modelled 
include the individual’s CD4 count, viral load, use of specific antiretroviral drugs, treatment 
interruptions, presence of resistance mutations and adherence levels. The risk of loss to 
follow-up, AIDS events, AIDS deaths and non-AIDS deaths are also modelled.  
The model is used to simulate details for all individuals who have lived with HIV in the UK 
at any time from the beginning of the epidemic (assumed to be 1980) until 2015. For the 
purposes of calibrating to data from the UK, individuals are categorised into risk groups as 
MSM, black African heterosexuals, and all other individuals. This latter category includes all 
other heterosexual individuals, people who inject drugs (PWID) and other less common 
routes of HIV acquisition. Risk groups are not categorised further as the main aim of this 
study is to produce estimates for the PLHIV population as a whole. 
The model simulates longitudinal data on people from the time of infection. For risk groups 
other than black Africans, for simplicity, individuals are assumed to have lived in the UK at 
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the time of infection. We also assume that some black Africans living with HIV in the UK 
were likewise infected after migration to the UK. In addition, in order to capture the effects of 
migration to the UK of people already living with HIV from sub Saharan Africa, we simulate 
a “pool” of HIV-positive people born and living in sub-Saharan Africa (Figure 1). From this 
population, we assume a rate of migration. This rate of arrival into the UK from the pool of 
people who acquired HIV in sub-Saharan Africa is assumed to have the same trend as 
observed migration trends seen for the general population[18]. Additionally, we assume that 
the rate of arrival would be reduced to 0 (i.e. an individual will not migrate to the UK) in the 
presence of any pre-AIDS symptoms or AIDS-defining conditions. In order to simulate the 
population pool of people living with HIV in sub-Saharan Africa we use the HIV incidence 
curve from sub-Saharan Africa based on UNAIDS estimates generated using 
Spectrum/EPP[2, 3, 19].  
Whilst HIV testing in the UK was possible from 1984 onwards[20], the possibility of 
diagnosis for people whilst in sub-Saharan Africa is assumed only to be available from 1996 
onwards (when testing in antenatal clinics started), with the probability increasing with time. 
ART is assumed to be available for people in sub-Saharan Africa from 2000 (with scale-up 
from 2003 onwards) as per WHO guidelines at the time.  
Calibration to data 
The model is calibrated using Approximate Bayesian Computation (ABC) methods[21], 
which involves running the simulation model multiple times, each time sampling values for a 
set of input parameters from their respective prior distributions. ABC methods are suitable for 
complex simulation models where the likelihood of the outputs cannot be exactly calculated. 
It also allows us to explore a wide parameter space and to consider multiple sets of parameter 
values which are consistent with the observed data, instead of converging to a single set of 
parameter values.  
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For any single simulation, we define the ‘calibration-score’ to be the weighted average of the 
deviances of the modelled outputs from the observed data. Therefore, the lower the 
calibration-score, the better the model fits to the data. The calibration process is continued 
until at least 50 accepted sets of parameter values are within the pre-defined tolerance 
threshold. We chose to simulate at least 50 parameter sets due to the trade-off between 
precision and run time. Further simulations are then performed using the accepted parameter 
sets, to reduce stochastic variability (i.e. variability in model outputs between simulation runs 
when using the same parameter set). We use the 50 best fitting simulations generated in this 
step for our presented results; the median, 5th and 95th percentiles of the distribution of these 
model outputs are considered the point estimate and plausibility range (PR) limits, 
respectively. The main parameter values to be estimated are those associated with the 
incidence (in the UK) and rate of diagnosis. All risk groups are jointly modelled and 
calibrated. Further details of the calibration method are described in [14] and in the 
Supplementary material, http://links.lww.com/QAD/B16. The model and calibration method 
are programmed in SAS software, Version 9.3 (SAS Institute Inc., Cary, NC). 
Data from the HIV and AIDS reporting system (HARS), which is the national HIV 
surveillance system developed and managed by Public Health England (PHE), were used to 
calibrate the model. We used case-based reports on the number of new HIV diagnoses, 
number of deaths and CD4 count at diagnosis. Data collected on those diagnosed and 
accessing care, such as the number seen in care and number receiving ART, and time of 
arrival for sub-Saharan African migrants were also used. The observed data were available 
until 2013. Weights for each type of data used to calculate the calibration-score are chosen a 
priori to reflect perceived relative quality and completeness. Although HIV surveillance in 
the UK is based on voluntary reports from clinicians, virologists, public health practitioners 
amongst others, it is thought to be one of the most comprehensive in the world due to the 
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diverse range and methods by which information is collected and its direct link to the 
commissioning of HIV services. 
 
Results 
A range of model outputs from the simulations using the 50 accepted parameter sets 
alongside the surveillance data are presented in the Supplementary Materials, 
http://links.lww.com/QAD/B16. The following results are based on these parameter sets 
which are calibrated to the observed data in the UK.  
Principal findings 
The incidence of HIV, defined as the number of new infections acquired in the UK per year, 
is estimated to have remained at high levels in recent years (Figure 2). After the initial peak 
in incidence in 1980-81 with an average of 5,400 new infections per year, it is estimated to 
have steadily declined to an average of 1,600 infections in the early 1990s. The incidence is 
estimated to have risen to over 4,500 new infections per year since the 2000s. Between 2010 
and 2013, an estimated 4,700 (90% PR: 2,000-9,800) new infections occurred annually. This 
wide PR arises because there is a time lag between individuals acquiring HIV to then being 
diagnosed and reported into the surveillance system, meaning there is less data to inform the 
incidence for later years.  
By 2013, 106,400 (90% PR: 88,700-124,600) people were estimated to be living with HIV in 
the UK (Figure 3). As expected, there has been a sharper rise in the number of PLHIV in the 
post-combination therapy era due to the high effectiveness of ART in reducing death rates 
and non-zero incidence.  
The estimated total number of people living with undiagnosed HIV in 2013 was 24,600 (90% 
PR: 15,000-36,200) (Figure 3). This figure has remained stable during the last decade. Of the 
24,600 undiagnosed population living in the UK, 32% (8,000; 90% PR: 4,500-12,100) are 
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estimated to have CD4 count <350 cells/mm3 and are therefore at higher risk of progression 
to AIDS or clinical manifestation. We also estimate that 95% of the undiagnosed population 
have a viral load >500 copies/ml.  
The estimated HIV cascade of care for the UK in 2013 according to our model is shown in 
Figure 4. Using our estimate of the total number of people living with HIV (100%), 77% are 
diagnosed, 76% are retained in care, 68% are receiving ART and 62% have viral load <50 
copies/ml.  
Estimates by risk group 
Of the 4,700 new infections which took place in the UK each year between 2010 and 2014, 
we estimate that 2,500 (90% PR: 900-5,800) were attributed to MSM. We also estimate that 
1,200 (90% PR: 800-2,300) new infections were acquired annually in the UK in the same 
period among black African heterosexual individuals.    
The rate of diagnosis, defined as the probability of being diagnosed in the UK per year (given 
the person is HIV-positive and asymptomatic), is estimated to have increased over time to 
18.9% and 15.3% for MSM and heterosexual individuals (regardless of ethnicity or sex) for 
2008 onwards (it is assumed constant over eight year periods).  
As expected, PLHIV population size has increased in all risk groups (Figure 5), though the 
rise seems most substantial among MSM. In 2013, MSM comprised the largest share of the 
HIV-positive population in the UK, approximated at 45,000 (90% PR: 30,100-53,800). The 
next largest groups are black African females and black African males, with an estimated 
21,900 (90% PR: 17,700-27,900) and 15,400 (90% PR: 13,700-19,100) individuals 
respectively. Reduced migration from sub-Saharan Africa is believed to be the reason for a 
reduced rise in the total number of black African heterosexual individuals living with HIV 
and for the decline in the number living with undiagnosed HIV.  
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The estimated size of the undiagnosed proportion in 2013 ranges from 19% (90% PR: 9%-
28%) among MSM, to 26% (90% PR: 23%-30%) and 25% (90% PR: 22%-26%) in black 
African male and female heterosexuals and 23% (90% PR: 17%-34%) and 20% (90% PR: 
15%-33%) in all other males and females respectively. The proportion of undiagnosed people 
with a CD4 count <350 cells/mm3 varies greatly between risk groups, with an estimated 27% 
among MSM but a substantially higher 46% for black African heterosexuals.   
 
Discussion 
Our modelling study shows that the total number of PLHIV in the UK in 2013 surpassed 
100,000, with around a fifth to a quarter of this population being unaware of their infection. 
The model we have used has been calibrated to a wide range of UK surveillance data, 
including data on black African heterosexuals, in order to provide a more detailed picture of 
the national epidemic than has been done before.  
There is a distinct possibility that the incidence of new infections taking place in recent years 
is even greater than the high levels seen at the beginning of the epidemic, although there is 
large uncertainty associated with it. We estimated that there were nearly 5,000 new cases of 
HIV occurring in the UK in 2013. This is despite the fact that nearly two-thirds of the PLHIV 
population are thought to be virally suppressed and at low risk of transmitting the virus. 
Although national and international guidelines now recommend that all PLHIV should 
initiate ART[22, 23], studies have shown that HIV transmission in the UK is largely driven 
by the undiagnosed population and that testing rates need to be much higher in order to limit 
further increases in incidence[5, 24]. Higher testing rates are especially needed among black 
African individuals, for which we estimate that nearly half of those undiagnosed have CD4 
count <350 cells/mm3 and are in immediate need for treatment. 
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Our results are in line with previous estimates published by PHE, using the Multi-Parameter 
Evidence Synthesis (MPES) method[25, 26]. Like our model, the MPES method is directly 
informed by surveillance data, but is combined with other data from prevalence surveys and 
estimates of risk group sizes to calculate the prevalence of HIV and the size of the 
undiagnosed population. The MPES estimate for the total number of PLHIV in 2013 was 
107,800 (95% credible interval: 101,600-115,800)[10]. The PR generated using our method 
is considerably wider however, which is likely a result of taking into account the uncertainty 
associated with parameters which cannot be directly informed by data, as well as the beliefs 
held with regards to certain items of data (as quantified using different weights in the 
calibration-score). Our method is able to complement the information generated by the MPES 
method and provides another approach to estimate the undiagnosed population. The ECDC 
modelling tool[7, 27] is also a method based on an underlying mathematical model of HIV 
which can estimate incidence and the total size of the diagnosed and undiagnosed population, 
however it does not currently take into account migration. 
To the best of our knowledge, our study is the first modelling study done to characterize the 
PLHIV population in a European context which attempts to address and incorporate 
migration of individuals from endemic settings. Migrants from sub-Saharan Africa account 
for a significant proportion of cases of HIV in Europe[28, 29], and it is important to fully 
consider this population in estimates and to try to disentangle the extent to which 
transmission is ongoing in the European country[30]. In settings where a large number of 
infections are thought to have occurred abroad, it is important to know how many PLHIV 
actually acquired their infection in the country of interest, in order to target prevention 
interventions most effectively. It was used to be considered that most migrants acquired HIV 
in sub-Saharan Africa, however more recent evidence suggests that in fact many are now 
acquiring HIV post-migration in European countries[12, 31]. Here we estimated that 1,200 
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(90% PR: 800-2,300) new infections occurred annually in the UK among black African 
heterosexuals in 2010-2014. In addition, we estimate that there has been a decline in the 
number of undiagnosed black African heterosexuals, and that many are likely to be diagnosed 
late, which in turn means that testing is imperative among this group.  
Our estimates are based on our model being calibrated to the date of arrival into the UK 
among HIV-positive individuals from sub-Saharan Africa. These data are not collected as 
part of routine case surveillance in all countries at present however this field is now 
recommended by the European Centre for Disease Prevention and Control[32]. We also 
acknowledge that few countries have a national cohort of all people living with diagnosed 
HIV. These data are a critical part of the model calibration. 
One limitation with this modelling study was that we did not explicitly model heterosexual 
individuals who are not black African, PWID, mother-to-child-transmission or other less 
common routes, but instead grouped them together. This also means that we were not able to 
make separate estimates of the size of these risk groups. In 2013, PHE figures stated that 
4.3% of cases of new HIV diagnoses were acquired through injecting drug use or other routes 
of transmission (not including sexual transmission) and there are also a small proportion of 
cases without an exposure category[10]. For our risk group-specific estimates (but not our 
overall estimates) we also inherently assumed that the available data on route of HIV 
transmission is correct for each individual. Phylogenetic analyses in the UK have shown that 
some self-reported heterosexual men diagnosed with HIV could have acquired HIV through 
sex with other men, choosing not to disclose sex with men at HIV diagnosis and preferring to 
be identified as heterosexual[33, 34].  
Our main aim was to estimate the total size of the PLHIV population and therefore the model 
is more closely calibrated to un-stratified data. This was done by calculating the calibration-
score using higher weights for data relating to the total population compared to risk group-
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
specific data. Specifically, we used weights which were twice as much because it was 
important that the model outcomes were more closely calibrated to data on the total UK 
population. This means our estimates presented for the three defined groups are not as well 
informed as the overall presented estimates for the UK. For example, the point estimate of 
2,500 (90% PR: 900-5,800) new infections among MSM per year for 2010-2014 is lower 
than the estimate of 3,200 (90% PR: 1,700-5,400) from our previous work where the model 
was specifically calibrated to data on MSM[14]. Further research is required to model the 
migrant population more accurately, in order to better estimate incidence and number 
undiagnosed. Similarly, narrower PRs may well also follow by modelling sub-populations 
separately by reducing the realm to which the model needs to fit the observed data. 
In addition, our method of estimating the UK PLHIV population is not easy to implement, 
requiring knowledge of mathematical models and being computer intensive. It should also be 
noted that our PRs are wide as we take into account many sources of error and variability. 
However, they are perhaps overestimated somewhat due to residual stochastic effects relating 
to the fact that we model a random sample of the infected population and scale up. Although 
generally, more data should lead to less uncertainty, there is a limit to how much the PRs can 
be reduced, given that in this case, what we are trying to estimate is intrinsically uncertain.  
Achieving the UNAIDS 90-90-90 target requires more than 73% of all PLHIV with an 
undetectable viral load[35]. Even in the UK, where HIV services are comprehensive and 
universally free, we estimate that only 62% of the PLHIV population have suppressed viral 
load. In a previous modelling study, we showed that 90% of all HIV-positive MSM would 
need to be suppressed to achieve substantial reductions in incidence[9]. In most settings, 
including the UK, the largest breakpoint in the cascade is diagnosis, reiterating the 
importance of testing[36]. It is recognised that late diagnosis, particularly among 
heterosexuals remains a problem in the UK[10]. There is therefore a need for scaling up 
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access to HIV testing, and frequency of testing in those at high risk, to reduce late diagnoses 
and also undiagnosed HIV infection, which is the likely reason for ongoing levels of high 
incidence.   
It is possible with access to good surveillance data to calculate the proportion of the 
diagnosed population who are on ART and the proportion of the treated population who are 
virally suppressed. However, it is not possible to know the size of the undiagnosed population 
without some estimation method such as mathematical models or prevalence surveys. The 
method presented and used here allows calculation of such information which are vital to 
know the extent to which targets such as those put in place by UNAIDS are likely to be 
achieved. It is only feasible to generate reliable estimates of the number of people living with 
HIV if good surveillance data are available however. Our modelling work is based on 
extensive national-level surveillance data, and though it would not be impossible to do 
without all of it, a similarly strong set of data is required for it to be applied in another 
setting.    
In conclusion, we have presented a method to generate national-level estimates about the size 
and characteristics of HIV-positive populations incorporating migrants from sub-Saharan 
Africa. These estimates should help inform and evaluate current and future public health 
responses to the epidemic by providing more information about the affected population than 
can be understood and achieved solely from surveillance.  
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